A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6625-33.

View in: PubMed

subject areas

Administration, Oral
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal
Area Under Curve
Capsules
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Drug Resistance, Neoplasm
Estradiol
Female
Fibroblast Growth Factor 2
Humans
Male
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms
Time Factors
Treatment Outcome
Vascular Endothelial Growth Factor A

authors with profiles

GEORGE WILDING